Oncogenic K-ras and loss of smad4 mediate invasion by activating an EGFR/NF-?B Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Bera, Alakesh ^a   Zhao, Shujie ^a   Cao, Lin ^a   Chiao, Paul J ^d   Freeman, James W ^a,b,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b San Antonio Cancer Institute   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN UPA; SMAD4 PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ARTICLE; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PANCREAS CELL; PHARMACOLOGICAL BLOCKING; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SMAD4 GENE; UPREGULATION;

CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TRANSFORMED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSCRIPTION FACTOR RELA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84891943964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082282     Document Type: Article

References (63)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. doi:10.3322/CA.2007.0010. PubMed: 18287387. (Pubitemid 351521864)
2. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S et al. (2001) Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7: 2396-2404. PubMed: 11489818. (Pubitemid 32751641)
3. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34. doi:10.1007/ s10555-006-7886-9. PubMed: 16680569. (Pubitemid 43723979)
4. Duffy MJ (2002) Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48: 1194-1197. PubMed: 12142372. (Pubitemid 34809824)
5. Lynch HT, Brand RE, Lynch JF, Fusaro RM, Kern SE (2002) Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg 9: 12-31. doi:10.1007/s005340200001. PubMed: 12021894. (Pubitemid 34477367)
6. Kern SE, Hruban RH, Hidalgo M, Yeo CJ (2002) An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther 1: 607-613. PubMed: 12642681.
7. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909. doi:10.1038/nri951. PubMed: 12459728. (Pubitemid 37328891)
8. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S (2003) Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 22: 153-166. doi:10.1023/A:1023091214123. PubMed: 12784994. (Pubitemid 36561055)
9. Nagase H, Woessner JF Jr. (1999) Matrix metalloproteinases. J Biol Chem 274: 21491-21494. doi:10.1074/jbc.274.31.21491. PubMed: 10419448. (Pubitemid 29359963)
10. Stamenkovic I (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415-433. doi:10.1006/scbi. 2000.0379. PubMed: 11170864. (Pubitemid 32181912)
11. Alfano M, Sidenius N, Blasi F, Poli G (2003) The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. J Leukoc Biol 74: 750-756. doi:10.1189/jlb.0403176. PubMed: 12960238. (Pubitemid 38040351)
12. Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222. doi:10.1023/A:1023099415940. PubMed: 12784997. (Pubitemid 36561058)
13. McCawley LJ, O'Brien P, Hudson LG (1998) Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)- mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol 176: 255-265 (Pubitemid 28319709)
14. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y et al. (2004) Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279: 24505-24513. doi:10.1074/jbc. M400081200. PubMed: 15044465. (Pubitemid 38725316)
15. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM (2003) Immortalization with telomeRase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 301: 1038-1044. doi: 10.1016/S0006-291X(03)00086-X. PubMed: 12589817. (Pubitemid 36279217)
16. Zhao S, Wang Y, Cao L, Ouellette MM, Freeman JW (2010) Expression of oncogenic K-Ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer 127: 2076-2087. doi: 10.1002/ijc.25412. PubMed: 20473902.
17. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V et al. (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3- kinase signaling. Cancer Res 67: 2098-2106. doi: 10.1158/0008-5472.CAN-06-3752. PubMed: 17332339. (Pubitemid 46424228)
18. Nishi H, Neta G, Nishi KH, Akers LM, Rikiyama T et al. (2003) Analysis of the epidermal growth factor receptor promoter: the effect of nuclear factor-kappaB. Int J Mol Med 11: 49-55. PubMed: 12469217.
19. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S et al. (2001) The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 276: 8865-8874. doi:10.1074/ jbc.M008458200. PubMed: 11116146.
20. Hirota K, Murata M, Itoh T, Yodoi J, Fukuda K (2001) Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J Biol Chem 276: 25953-25958. doi:10.1074/jbc.M011021200. PubMed: 11337489. (Pubitemid 37412801)
21. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227. doi:10.1038/nrm775. PubMed: 11875461.
22. Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y et al. (2009) Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 15: 2248-2258. doi:10.1158/1078-0432.CCR-08-1383. PubMed: 19276252.
23. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB et al. (2003) Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7: 37-43; discussion: 10.1016/ S1091-255X(02)00088-4. PubMed: 12559183. (Pubitemid 36875799)
24. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG et al. (2003) Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 9: 346-354. PubMed: 12538487. (Pubitemid 36109751)
25. Zhao S, Ammanamanchi S, Brattain M, Cao L, Thangasamy A et al. (2008) Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells. J Biol Chem 283: 11293-11301. doi:10.1074/ jbc.M800154200. PubMed: 18310076.
26. Marshall BC, Sageser DS, Rao NV, Emi M, Hoidal JR (1990) Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem 265: 8198-8204. PubMed: 2110565.
27. Schwingshackl A, Duszyk M, Brown N, Moqbel R (1999) Human eosinophils release matrix metalloproteinase-9 on stimulation with TNFalpha. J Allergy Clin Immunol 104: 983-989. doi:10.1016/ S0091-6749(99)70079-5. PubMed: 10550743.
28. Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C et al. (2011) Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res 71: 277-286. doi:10.1158/0008-5472.CAN-10-2523. PubMed: 21199807.
29. Lee CW, Lin CC, Lin WN, Liang KC, Luo SF et al. (2007) TNF-alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/ PI3K/Akt cascade and promotion of NF-kappaB/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 292: L799-L812. PubMed: 17158602.
30. Kim S, Choi JH, Lim HI, Lee SK, Kim WW et al. (2009) EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal 21: 892-898. doi:10.1016/j.cellsig.2009.01.034. PubMed: 19385051.
31. Farina AR, Tacconelli A, Vacca A, Maroder M, Gulino A et al. (1999) Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ 10: 353-367. PubMed: 10359016. (Pubitemid 29242601)
32. Novak U, Cocks BG, Hamilton JA (1991) A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 19: 3389-3393. doi:10.1093/nar/19.12.3389. PubMed: 1905804. (Pubitemid 21912698)
33. Sun L, Carpenter G (1998) Epidermal growth factor activation of NFkappaB is mediated through IkappaBalpha degradation and intracellular free calcium. Oncogene 16: 2095-2102. doi:10.1038/sj.onc. 1201731. PubMed: 9572490. (Pubitemid 28211684)
34. Biswas DK, Cruz AP, Gansberger E, Pardee AB (2000) Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97: 8542-8547. doi:10.1073/ pnas.97.15.8542. PubMed: 10900013. (Pubitemid 30639709)
35. Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F (2005) EGFR and Her-2 regulate the constitutive activation of NFkappaB in PC-3 prostate cancer cells. Prostate 65: 130-140. doi: 10.1002/pros.20234. PubMed: 15880609. (Pubitemid 41362280)
36. Bellezza I, Tucci A, Galli F, Grottelli S, Mierla AL et al. (2012) Inhibition of NF-kappaB nuclear translocation via HO-1 activation underlies alpha-tocopheryl succinate toxicity. J Nutr Biochem 23: 1583-1591. doi: 10.1016/j.jnutbio.2011.10.012. PubMed: 22444871.
37. Poggi A, Pellegatta F, Leone BE, Moretta L, Zocchi MR (2000) Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias. Eur J Immunol 30: 2751-2758. doi: 10.1002/1521-4141(200010)30:10. PubMed: 11069054.
38. Zhu BS, Xing CG, Lin F, Fan XQ, Zhao K et al. (2011) Blocking NFkappaB nuclear translocation leads to p53-related autophagy activation and cell apoptosis. World J Gastroenterol 17: 478-487. doi:10.3748/ wjg.v17.i4.478. PubMed: 21274377.
39. Jeong KJ, Park SY, Cho KH, Sohn JS, Lee J et al. (2012) The Rho/ ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene, 31: 4279-89. PubMed: 22249252.
40. Zhang T, Yu H, Dong G, Cai L, Bai Y (2013) Chamaejasmine arrests cell cycle, induces apoptosis and inhibits nuclear NF-kappaB translocation in the human breast cancer cell line MDA-MB-231. Molecules 18: 845-858. doi:10.3390/molecules18010845. PubMed: 23344197.
41. Shant J, Cheng K, MaRasa BS, Wang JY, Raufman JP (2009) Aktdependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res 315: 432-450. doi:10.1016/j.yexcr. 2008.11.003. PubMed: 19056378.
42. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K et al. (2002) Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100: 1828-1834. doi:10.1182/blood-2002-01-0151. PubMed: 12176906. (Pubitemid 34925163)
43. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 0010.
44. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J et al. (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058. doi:10.1172/JCI32278. PubMed: 17671639. (Pubitemid 47224766)
45. Korc M, Meltzer P, Trent J (1986) Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A 83: 5141-5144. doi:10.1073/pnas.83.14.5141. PubMed: 3014534. (Pubitemid 16051332)
46. Korc M, ChandRasekar B, Yamanaka Y, Friess H, Buchier M et al. (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90: 1352-1360. doi:10.1172/JCI116001. PubMed: 1401070.
47. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ (2000) Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 10: 147-154
48. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F et al. (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279. doi:10.1016/j.advenzreg.2006.01. 004. PubMed: 16854453. (Pubitemid 44301348)
49. Bierie B, Moses HL (2006) TGF-beta and cancer. Cytokine Growth Factor Rev 17: 29-40. doi:10.1016/j.cytogfr.2005.09.006. PubMed: 16289860. (Pubitemid 43117514)
50. Kojima K, Vickers SM, Adsay NV, Jhala NC, Kim HG et al. (2007) Inactivation of Smad4 accelerates KRas(G12D)-mediated pancreatic neoplasia. Cancer Res 67: 8121-8130. doi: 10.1158/0008-5472.CAN-06-4167. PubMed: 17804724. (Pubitemid 47395147)
51. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA et al. (2003) Activated KRas and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126. doi:10.1101/gad. 1158703. PubMed: 14681207. (Pubitemid 38040774)
52. Siveke JT, Einwächter H, Sipos B, Lubeseder-Martellato C, Klöppel G et al. (2007) Concomitant pancreatic activation of KRas(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12: 266-279. doi:10.1016/j.ccr.2007.08.002. PubMed: 17785207. (Pubitemid 47333415)
53. Kretzschmar M, Doody J, Timokhina I, Massagué J (1999) A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 13: 804-816. doi:10.1101/gad.13.7.804. PubMed: 10197981. (Pubitemid 29169840)
54. Xu D, Lillico SG, Barnett MW, Whitelaw CB, Archibald AL et al. (2012) USP18 restricts PRRSV growth through alteration of nuclear translocation of NF-kappaB p65 and p50 in MARC-145 cells. Virus Res 169: 264-267. doi:10.1016/j.virusres.2012.07.002. PubMed: 22796444.
55. Tao Y, Chen YC, Lan T, Qian H, Wang Y et al. (2012) LPS-induced nuclear translocation of RhoA is dependent on NF-kappaB in the human lung cancer cell line A549. Oncol Lett 3: 1283-1287. PubMed: 22783434.
56. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR et al. (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127. PubMed: 9918209. (Pubitemid 29045184)
57. Wang W, Abbruzzese JL, Evans DB, Chiao PJ (1999) Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 18: 4554-4563. doi:10.1038/sj.onc. 1202833. PubMed: 10467400. (Pubitemid 29405887)
58. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H et al. (2011) CARMA3 is crucial for EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res 71: 2183-2192. doi: 10.1158/0008-5472.CAN-10-3626. PubMed: 21406399.
59. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB et al. (2003) NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 91: 417-420. doi:10.1046/j.1464-410X. 2003.04104.x. PubMed: 12603426. (Pubitemid 36359653)
60. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M et al. (1992) A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 11: 205-213. PubMed: 1740106.
61. Perona R, Montaner S, Saniger L, Sánchez-Pérez I, Bravo R et al. (1997) Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 11: 463-475. doi:10.1101/gad.11.4.463. PubMed: 9042860. (Pubitemid 27097645)
62. Bond M, Fabunmi RP, Baker AH, Newby AC (1998) Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435: 29-34. doi:10.1016/S0014-5793(98)01034-5. PubMed: 9755853. (Pubitemid 28432009)
63. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF (2003) Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res 63: 1359-1364. PubMed: 12649199. (Pubitemid 36348717)